Pharming Group N.V. (AMS:PHARM)
Netherlands · Delayed Price · Currency is EUR 1.170
-0.016 (-1.35%)
May 27, 2026, 1:45 PM CET
Pharming Group Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 369.49 | 376.13 | 297.2 | 245.32 | 205.62 | 198.87 | |
Revenue Growth (YoY) | 15.21% | 26.56% | 21.15% | 19.30% | 3.40% | -6.27% |
Cost of Revenue | 43.82 | 45.5 | 35.4 | 25.21 | 17.56 | 21.14 |
Gross Profit | 325.67 | 330.63 | 261.8 | 220.1 | 188.06 | 177.73 |
Selling, General & Admin | 190.84 | 202.36 | 184.43 | 175.26 | 127.44 | 90.97 |
Research & Development | 102.58 | 98.17 | 83.15 | 68.66 | 52.53 | 65.38 |
Other Operating Expenses | -2.65 | -2.65 | -2.18 | -2.07 | -2.28 | -2.62 |
Operating Expenses | 290.78 | 297.88 | 265.4 | 241.85 | 177.69 | 153.73 |
Operating Income | 34.89 | 32.76 | -3.59 | -21.75 | 10.37 | 24 |
Interest Expense | -8.32 | -10.72 | -8.74 | -5.96 | -5.36 | -6.09 |
Interest & Investment Income | 4.81 | 2.18 | 4.86 | 3.66 | 0.09 | 0.05 |
Earnings From Equity Investments | 0.49 | 0.62 | -1.76 | -0.29 | -1.08 | 0.69 |
Currency Exchange Gain (Loss) | -7.23 | -7.23 | 1.99 | -2.97 | 4.4 | 14.84 |
Other Non Operating Income (Expenses) | 2.15 | 2.15 | 3.78 | -1.06 | -1.29 | -0.09 |
EBT Excluding Unusual Items | 26.8 | 19.76 | -3.47 | -28.38 | 7.12 | 33.4 |
Merger & Restructuring Charges | -10.3 | -10.3 | - | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | 12.24 | 0.11 |
Gain (Loss) on Sale of Assets | - | - | - | 21.28 | - | - |
Asset Writedown | -0.49 | -0.49 | -5.03 | -4.92 | -4.38 | -10.44 |
Other Unusual Items | 3.88 | 3.88 | - | - | - | - |
Pretax Income | 19.88 | 12.85 | -8.49 | -12.01 | 14.99 | 23.08 |
Income Tax Expense | 7.67 | 10.31 | 3.35 | -1.46 | 1.31 | 7.08 |
Earnings From Continuing Operations | 12.21 | 2.54 | -11.84 | -10.55 | 13.67 | 16 |
Minority Interest in Earnings | 0.14 | 0.31 | - | - | - | - |
Net Income | 12.36 | 2.85 | -11.84 | -10.55 | 13.67 | 16 |
Net Income to Common | 12.36 | 2.85 | -11.84 | -10.55 | 13.67 | 16 |
Net Income Growth | - | - | - | - | -14.52% | -57.62% |
Shares Outstanding (Basic) | 708 | 689 | 671 | 657 | 649 | 642 |
Shares Outstanding (Diluted) | 766 | 747 | 671 | 657 | 707 | 701 |
Shares Change (YoY) | 13.48% | 11.25% | 2.18% | -7.09% | 0.85% | 2.70% |
EPS (Basic) | 0.02 | 0.00 | -0.02 | -0.02 | 0.02 | 0.02 |
EPS (Diluted) | 0.02 | 0.00 | -0.02 | -0.02 | 0.02 | 0.02 |
EPS Growth | - | - | - | - | -17.39% | -58.18% |
Free Cash Flow | 55.72 | 53.96 | -2.59 | -18.74 | 21.08 | 27.1 |
Free Cash Flow Per Share | 0.07 | 0.07 | -0.00 | -0.03 | 0.03 | 0.04 |
Gross Margin | 88.14% | 87.90% | 88.09% | 89.72% | 91.46% | 89.37% |
Operating Margin | 9.44% | 8.71% | -1.21% | -8.87% | 5.04% | 12.07% |
Profit Margin | 3.34% | 0.76% | -3.98% | -4.30% | 6.65% | 8.04% |
Free Cash Flow Margin | 15.08% | 14.35% | -0.87% | -7.64% | 10.25% | 13.63% |
EBITDA | 42.28 | 39.62 | 3.22 | -15.29 | 17.13 | 30.39 |
EBITDA Margin | 11.44% | 10.53% | 1.08% | -6.23% | 8.33% | 15.28% |
D&A For EBITDA | 7.39 | 6.86 | 6.82 | 6.46 | 6.76 | 6.39 |
EBIT | 34.89 | 32.76 | -3.59 | -21.75 | 10.37 | 24 |
EBIT Margin | 9.44% | 8.71% | -1.21% | -8.87% | 5.04% | 12.07% |
Effective Tax Rate | 38.57% | 80.25% | - | - | 8.76% | 30.69% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.